A3 Adenosine Receptor Signaling Contributes to Airway Inflammation and Mucus Production in Adenosine Deaminase-Deficient Mice1

Adenosine signaling has been implicated in chronic lung diseases such as asthma and chronic obstructive pulmonary disease; however, the specific roles of the various adenosine receptors in processes central to these disorders are not well understood. In this study, we have investigated the role(s) of the A3 adenosine receptor in adenosine-dependent pulmonary inflammation observed in adenosine deaminase (ADA)-deficient mice. The A3 receptor (A3R) was found to be expressed in eosinophils and mucus-producing cells in the airways of ADA-deficient mice. Treatment of ADA-deficient mice with MRS 1523, a selective A3R antagonist, prevented airway eosinophilia and mucus production. Similar findings were seen in the lungs of ADA/A3 double knockout mice. Although eosinophils were decreased in the airways of ADA-deficient mice following antagonism or removal of the A3R, elevations in circulating and lung interstitial eosinophils persisted, suggesting signaling through the A3R is needed for the migration of eosinophils into the airways. These findings identify an important role for the A3R in regulating lung eosinophilia and mucus production in an environment of elevated adenosine.

A sthma and chronic obstructive pulmonary disease (COPD) 4 are lung diseases that afflict millions of individuals and result in billions of dollars in annual heath care cost. In contrast to most injury and repair responses, the inflammation seen in these disorders is chronic and may last throughout the life of the afflicted individual. Although signaling pathways associated with the genesis of inflammation and the control of tissue remodeling have been described (1,2), little is known about signaling pathways that serve to regulate the chronic nature of these diseases.
Adenosine is a potent and ubiquitous signaling nucleoside that is generated at sites of tissue damage and hypoxia. Accordingly, adenosine levels are elevated in the bronchoalveolar lavage fluid (BALF) (3) and exhaled breath condensate (4) of asthmatic patients where significant lung inflammation and hypoxia exist. These elevations suggest that adenosine signaling may regulate aspects of chronic lung disease. This hypothesis is supported by recent studies demonstrating that elevations in adenosine evoke signaling pathways that lead to chronic lung disease in mice (5)(6)(7). Additional evidence linking adenosine to asthma and COPD include the observations that exposing patients to exogenous adenosine can elicit bronchoconstriction, whereas adenosine has little effect on control subjects (8 -11). However, relatively little is known about the function of adenosine signaling on specific cell types in the inflamed lung.
Adenosine engages distinct subtypes of P1 purinergic receptors (A 1 , A 2A , A 2B , and A 3 adenosine receptors), which are seven transmembrane proteins that couple to heterotrimeric G-proteins (12). Engagement of adenosine receptors is associated with both pro-and anti-inflammatory actions that are dictated by specific receptor subtypes, downstream signaling components and levels of available ligand (12)(13)(14). The A 3 adenosine receptor A 3 R has emerged as an adenosine receptor subtype that may serve important regulatory roles in the inflamed lung. Walker et al. (15) demonstrated that transcript levels for the A 3 R are elevated in lung biopsies of patients with asthma or COPD, suggesting increased signaling through this receptor. Moreover, numerous in vivo and ex vivo studies suggest that A 3 R signaling can influence inflammatory cell types associated with asthma and COPD (16 -22). In rodents, airway mast cells express the A 3 R (22) and engagement of this receptor can promote (22) or enhance (23,24) mediator release from mast cells. In addition, human eosinophils express the A 3 R (25); however, the function of A 3 R signaling on this cell type remains controversial with both pro- (26) and anti- (17) inflammatory activities being reported. Expression of the A 3 R in the asthmatic lung (15) in association with adenosine elevations (3), suggests A 3 R engagement may regulate features of this disease. However, studies examining the importance of the A 3 R in inflamed lungs that exhibit elevations in adenosine are lacking.
Adenosine deaminase (ADA) is a purine catabolic enzyme that converts adenosine to inosine, and in so doing helps to regulate the levels of adenosine present in tissues and cells. Consistent with this, mice deficient in ADA exhibit elevations in adenosine in many organs including the lung (27). ADA-deficient mice develop features of chronic lung disease in association with elevations in lung adenosine concentrations (5). Features seen include the accumulation of eosinophils and activated macrophages in the airways, mucus metaplasia in the bronchial airways, and airway destruction. Many of the pulmonary features seen in ADA-deficient mice are reversible following the lowering of lung adenosine levels using ADA enzyme therapy (5,6,28,29), suggesting that adenosine signaling plays an important role in the exacerbation of pulmonary inflammation and airway remodeling. The current study examines the role(s) of the A 3 R in the airway inflammation seen in ADA-deficient mice. Findings suggest that the A 3 R plays a proinflammatory role in ADA-deficient airway disease by contributing to airway inflammation and mucus production.

Generation of polyethylene glycol (PEG) modified ADA
Calf intestine ADA (Roche Applied Sciences, Indianapolis, IN) was diluted to 500 U/ml in 1 ml of sterile PBS, pH 9.0. The diluted ADA was dialyzed for 16 h in 2 changes of 500 ml of PBS, pH 9.0. Next, 100 mg/ml mPEG-SPA, molecular mass 20,000 Da (Nektar Therapeutics, Huntsville, AL) was added, and the solution was mixed at room temperature for 5 h. Pegylation efficiency was assessed by zymogram analysis as described (30,31). Endotoxin was removed using AffinityPak Endotoxin Columns (Pierce, Rockford, IL). PEG-ADA activity was determined by spectrophotometric ADA enzyme assay (32), and diluted to a final concentration of 0.25 U/l in PBS, pH 7.4.

OVA sensitization and challenge
Six-wk-old BALB/c female mice were sensitized by an i.p. injection of 500 l (8 g/ml OVA (Sigma-Aldrich, St. Louis, MO) and 8 mg/ml alum (Sigma-Aldrich)) on days 0, 7, and 14 (33). Mice were challenged intranasally with 30 l of saline or OVA (8 mg/ml) on days 14, 21, 22, and 23, and were sacrificed 24 h after the last installation for collection of cells from the BALF.

In situ hybridization
In situ hybridization was conducted according to established protocols (35). Plasmids containing a portion of the A 3 R cDNA were linearized and either T3 or T7 RNA polymerases were used to generate antisense or sense riboprobes labeled with [␣-35 S]UTP. Samples were overlaid with 8 million counts of riboprobe and hybridized overnight at 60°C. Posthybridization washes were conducted as described (35), and slides were dipped in Kodak NTB-2 emulsion (Rochester, NY) and exposed for up to 6 wk.

Histology and period acid Schiff (PAS)/AB staining
Mice were sacrificed and the lungs inflated with 0.5 ml of fixative (4% paraformaldehyde in PBS) before fixation overnight at 4°C. Fixed lung tissues were embedded in paraffin and 5-m sections were stained with H&E using a Rapid Chrome staining kit (Thermo Shandon, Pittsburgh, PA). Similar sections were stained with PAS counterstained with Alcian blue (AB). The mucus index score was determined by dividing the ((area of PAS/AB staining) ϫ (mean intensity of PAS/AB staining)) by the total area of the airway epithelium (5).

Bronchoalveolar lavage and peripheral blood analysis
Mice were anesthetized, the trachea isolated by blunt dissection, and a small caliber catheter secured into the airways. Two volumes of 1 ml of PBS with 0.1% BSA were instilled and gently aspirated and pooled (BALF). Samples were then centrifuged at 2500 rpm for 5 min to recover cells. Cell pellets were resuspended in PBS and total cell counts determined using a hemocytometer. Aliquots were cytospun and stained for cellular differentials (5). Whole blood was collected from the tail vein and smeared onto microscope slides for differentials. Total peripheral white blood cell counts were determined on hemolysed aliquots using a hemocytometer.

Immunhistochemical analysis
Deparaffinized sections were rehydrated in a series of graded alcohols to water. Endogenous peroxidase activity was blocked by incubation in 0.5% H 2 O 2 in methanol for 20 min. Sections were then incubated for 1 h at room temperature with a 1/3000 dilution of rabbit anti-mouse major basic protein 1 (mMBP-1) Ab (36) followed by development with a rabbit IgG Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). Quantification of peribronchial eosinophils was assessed by analysis of 10 fields at ϫ20 magnification. The number of peribronchial eosinophils within a 0.6mm 2 area were counted using Image Pro Plus 4.0 image analysis software (Media Cybernetics, Silver Spring, MD).

Eosinophil chemotaxis assay
Chemotactic capacity of ADA Ϫ/Ϫ BALF was assayed as described previously (37). Briefly, the migration of purified eosinophils from the blood of IL-5 transgenic mice (38) was investigated using 3-m polycarbonate membrane transwell insets in 24-well tissue culture polystyrene plates (Costar, Corning, NY). The inserts contained eosinophils (1 ϫ 10 6 ) and 30 ng/ml recombinant mouse IL-5. Three eosinophil populations were examined: 1) purified eosinophils with no additional manipulation; 2) eosinophils pretreated with 100 nM IB-MECA; and 3) eosinophils treated initially with 5 M MRS 1523 followed by 100 nM IB-MECA. The inserts were then placed in the wells containing 500 l of medium alone or medium containing mouse eotaxin-1 (positive control), ADA control, or ADA Ϫ/Ϫ BALF. The plates were incubated at 37°C, 5% CO 2 for 90 min. The cells that had migrated to the lower chamber were collected and counted using a hemacytometer.

A 3 R transcripts in the lungs of ADA Ϫ/Ϫ mice
Total RNA was isolated from the lungs of 18-day-old mice and A 3 R transcripts were analyzed by RT-PCR. Although A 3 R transcripts were detectable in the lungs of both ADA control and ADA Ϫ/Ϫ mice, the prevalence of these transcripts increased in the lungs of ADA Ϫ/Ϫ mice (Fig. 1). These findings demonstrate that A 3 R transcript levels are elevated in the lungs of ADA Ϫ/Ϫ mice at a time when adenosine concentrations, eosinophil numbers, and mucus production are all increased in the lung (5).

Localization of A 3 R transcripts in the lungs of ADA Ϫ/Ϫ mice
Activation of the A 3 R can elicit various responses depending on the cell type and downstream signaling components involved (15-20, 22, 39). We examined the localization of A 3 R transcripts using in situ hybridization. A 3 R transcripts were not detectable in the lungs of ADA control mice ( Fig. 2A), whereas, transcripts for the A 3 R were abundant in the mucus-containing epithelial cells of ADA Ϫ/Ϫ mice (Fig. 2, C and D). Expression of the A 3 R was also seen in areas of inflammation (data not shown). These findings demonstrate that the increases in the A 3 R transcripts in the lungs of ADA Ϫ/Ϫ mice are located at sites of inflammation and mucus metaplasia.

Expression of the A 3 R in mouse eosinophils
General localization of A 3 R transcripts in inflammatory cells from the lungs of ADA Ϫ/Ϫ mice suggests that eosinophils may express the A 3 R. However, the cellular resolution of A 3 R expression was difficult using the in situ hybridization technique. Therefore, we quantified A 3 R transcripts in isolated eosinophils to confirm expression in this cell type. An established model of OVA sensitization and challenge (33) was used to generate a large number of airway eosinophils. Wild-type mice sensitized to OVA and challenged with saline (o/s) exhibited predominantly macrophages in the BALF (Fig. 3A), whereas mice challenged with OVA (o/o) exhibited a robust increase in BALF eosinophils (Fig. 3A). A 3 R transcript levels were markedly increased in RNA extracts from BALF cell pellets of o/o mice (Fig. 3B), suggesting A 3 R transcripts are present in eosinophils recruited to mouse airways. We FIGURE 1. Increased A 3 R expression in the lungs of ADA Ϫ/Ϫ mice. A, Total cellular RNA was isolated from the lungs of 18-day-old ADA control and ADA Ϫ/Ϫ mice and subjected to RT-PCR using primers specific for the A 3 R and ␤-actin. The (ϩ) control lane is total RNA from testes. B, TaqMan quantitative RT-PCR analysis of A 3 R transcripts was performed on whole lung RNA extracts from 18-day-old ADA control and ADA Ϫ/Ϫ mice. A 3 R values were normalized to ␤-actin transcript levels measured in the same RNA preparations. Values are mean Ϯ SEM, n ϭ 4. ‫,ء(‬ p Յ 0.05 using a Student's t test).

FIGURE 2. Localization of A 3 R transcripts to mucus-producing cells.
A, Darkfield image of an 18-day-old ADA control lung hybridized with antisense cRNA probe specific for the A 3 R. B, Serial section of the ADA control lung hybridized with A 3 sense cRNA probe. C, Brightfield image of an 18-day-old ADA Ϫ/Ϫ lung stained with PAS to illustrate areas of mucus production (arrows). D, Serial section of ADA Ϫ/Ϫ lung hybridized with the A 3 antisense cRNA probe. Arrows denote A 3 -specific expression. E, ADA Ϫ/Ϫ lung section hybridized with A 3 sense cRNA probe. Red pixels denote specific hybridization, while blue epifluorescence represents nuclei stained with Hoechst 33258 (A, B, D,  and E). Scale bar in A ϭ 100 m and applies to A-E. next examined A 3 R transcript levels in RNA isolated from eosinophils purified from the circulation of IL-5 transgenic mice (38). These eosinophils possessed no A 1 R transcript, and relatively low levels of A 2A R and A 2B R transcripts. In contrast, A 3 R transcripts were relatively abundant (Fig. 3C). Collectively, these data demonstrate that the A 3 R is expressed in mouse eosinophils recovered from both the circulation and the airways.

Effects of A 3 R antagonism on lung inflammation in ADA Ϫ/Ϫ mice
ADA Ϫ/Ϫ mice were treated with the A 3 R antagonist MRS 1523 to assess the contributions of A 3 R signaling to the adenosine-mediated pulmonary alterations in these mice. ADA Ϫ/Ϫ mice were maintained on ADA enzyme therapy until postnatal day 17 to allow the mice to mature to a size amenable to the implantation of osmotic pumps containing MRS 1523 (22). On postnatal day 19, mice were implanted with a s.c. osmotic pump containing either MRS 1523 (100 g/kg/day) or vehicle (saline). On postnatal days 29 -31, which was 12-14 days after the cessation of ADA enzyme therapy, adenosine levels were elevated in the lungs of ADA Ϫ/Ϫ mice (40). At this stage, various pulmonary endpoints were examined. ADA control mice treated with saline or MRS 1523 exhibited normal lung pathologies (Fig. 4, A and B), indicating that there   were no adverse responses due to pump implantation or A 3 R antagonism. In contrast, ADA Ϫ/Ϫ mice treated with saline exhibited increased pulmonary inflammation (Fig. 4C), and this inflammation was diminished by MRS 1523 treatment (Fig. 4D). Total cells infiltrating the airways of ADA Ϫ/Ϫ mice increased (Fig. 5A), and this increase was prevented by MRS 1523 treatment. The most abundant cell types found in these airways were macrophages and eosinophils (Fig. 5B). Treatment with MRS 1523 was associated with a decrease in all cell types in the airways, with an almost complete ablation of eosinophils (Fig. 5B). These data demonstrate that treatment with the A 3 R antagonist MRS 1523 can attenuate pulmonary inflammation and eosinophil infiltration into the airways of ADA Ϫ/Ϫ mice.

Localization of eosinophils in ADA Ϫ/Ϫ mice following antagonist treatment
Absence of eosinophils in the airways of ADA Ϫ/Ϫ mice treated with MRS 1523 prompted us to examine circulating and lung interstitial eosinophil numbers to determine whether A 3 R antagonism was affecting eosinophil production or trafficking. Lung interstitial eosinophils were localized using an Ab against mMBP-1 that is selectively produced by eosinophils (41). Few mMBP-1positive cells were observed in the peribronchial region of ADA control mice treated with saline or MRS 1523 (data not shown). In contrast, mMBP-1 positive eosinophils were readily detected in peribronchial regions of ADA Ϫ/Ϫ mice treated with saline (Fig.  6A). Interestingly, mMPB-1 positive eosinophils persisted in the peribronchial spaces of ADA Ϫ/Ϫ mice treated with MRS 1523 (Fig. 6B). Quantification of these findings demonstrated a significant decrease in interstitial lung eosinophilia in ADA Ϫ/Ϫ mice treated with MRS 1523; however, levels remained significantly elevated over control values (Fig. 6C). Examination of eosinophil levels in circulation revealed a significant increase in eosinophils in the circulation of ADA Ϫ/Ϫ mice treated with saline (Fig. 6D). This increase persisted in ADA Ϫ/Ϫ mice treated with MRS 1523, which was in marked contrast to the decreased eosinophilia seen in the BALF of these mice (Fig. 5B). Collectively, these data demonstrate that A 3 R antagonism does not affect the production of eosinophils in ADA Ϫ/Ϫ mice, and suggest that A 3 R signaling may impact eosinophil trafficking in the lungs.

Effects of MRS 1523 on mucus production in the airways of ADA Ϫ/Ϫ mice
Elevations in adenosine are associated with increased mucus production in the airways of ADA Ϫ/Ϫ mice (5). Mucus production was investigated in the airways of ADA Ϫ/Ϫ mice treated with MRS 1523 to determine the importance of A 3 R signaling in this process. ADA control mice treated with saline or MRS 1523 demonstrated little to no mucus production in their airways (Fig. 7, A,  B, and E). In contrast, saline-treated ADA Ϫ/Ϫ mice showed substantial airway mucus production (Fig. 7, C and E). ADA Ϫ/Ϫ mice treated with MRS 1523 exhibited a decrease in airway mucus production (Fig. 7, D and E). These findings were confirmed at the molecular level by examining Muc5ac and calcium-activated chloride channel 3 transcript levels in whole lung RNA extracts (data not shown). These data suggest that A 3 R signaling is important for  the development of adenosine-induced mucus production in this model.

Cytokine and chemokine levels in the lungs of MRS 1523-treated mice
Recruitment of inflammatory cells to the lung is associated with increased expression of proinflammatory cytokines and chemokines (2). Cytokine and chemokine levels were examined to determine whether A 3 R antagonism could impact the expression of these mediators. Levels of IL-5, IL-13, and IL-6 were elevated in the lungs of ADA Ϫ/Ϫ mice treated with saline, and levels continued to be elevated in the lungs of ADA Ϫ/Ϫ mice treated with MRS 1523 (Fig. 8A). Similar observations were made regarding the levels of the chemokines MCP-3, TARC, and eotaxin 1 (Fig. 8B). These findings demonstrate that increases in proinflammatory cytokines and chemokines in the lungs of ADA Ϫ/Ϫ mice occur in an A 3 R-independent manner.

Pulmonary phenotypes in ADA/A 3 double knockout mice
ADA Ϫ/Ϫ mice were crossed onto an A 3 Ϫ/Ϫ background to generate ADA/A 3 double knockout mice to genetically determine the contribution of the A 3 R to the lung disease seen in ADA Ϫ/Ϫ mice. Similar to what was seen following A 3 R antagonism, removal of the A 3 R resulted in diminished lung inflammation in ADA Ϫ/Ϫ FIGURE 9. Decreased airway inflammation and mucus production in ADA/A 3 double knockout mice. ADA control and ADA Ϫ/Ϫ mice with and without the A 3 R were maintained on PEG-ADA enzyme therapy until day 17 of age to match the pharmacologic protocol. Endpoints were examined at 28 -30 days of age. A, Cellular differentials given as mean total cell counts ϫ 10 5 Ϯ SEM, n ϭ 4. B, Peribronchial mMBP-1-positive eosinophils were quantified as described previously, values are presented as the number of eosinophils per mm 2 Ϯ SEM, n ϭ 3. C, White blood cells were counted from blood smears. Values are presented as the percent of total eosinophils per mm 3 Ϯ SEM, n ϭ 4. D, Mucus index scores were determined and values are presented as mucus index score Ϯ SEM, n ϭ 4. ‫,ء(‬ p Յ 0.05 ADA Ϫ/Ϫ A 3 ϩ/ϩ vs ADA control A 3 ϩ/ϩ ; #, p Յ 0.05 ADA Ϫ/Ϫ A 3 Ϫ/Ϫ vs ADA Ϫ/Ϫ A 3 ϩ/ϩ using a Student's t test). mice (Fig. 9A). In particular, there was a substantial decrease in the number of airway macrophages and eosinophils. The number of eosinophils found in the interstitial spaces surrounding bronchioles of ADA/A 3 double knockout mice were decreased (Fig. 9B); however, there was no decrease in the degree of eosinophilia in the circulation (Fig. 9C). In addition, cytokine and chemokine increases in the lungs of ADA/A 3 double knockouts were similar to those seen in ADA Ϫ/Ϫ mice treated with MRS 1523 (data not shown). These findings provide genetic evidence that A 3 R signaling contributes to inflammation and eosinophil trafficking in the lungs of ADA Ϫ/Ϫ mice. Mucus production was examined in ADA/A 3 double knockout mice to confirm the involvement of the A 3 R in this attribute of the ADA Ϫ/Ϫ pulmonary phenotype. As was seen following MRS 1523 treatment, genetic removal of the A 3 R was associated with decreased mucus production in the lungs of ADA Ϫ/Ϫ mice (Fig. 9D). These findings reiterate the importance of A 3 R signaling in the production of mucus in the lungs of ADA Ϫ/Ϫ mice.

Ex vivo effects of A 3 R signaling on eosinophil chemotaxis
Previous studies have demonstrated that engagement of the A 3 R on human eosinophils can inhibit chemotaxis ex vivo (15,18). To further examine the chemotactic properties in the lungs of ADA Ϫ/Ϫ mice, and to determine the impact of A 3 R signaling on mouse eosinophil chemotaxis ex vivo, purified mouse eosinophils were placed in chemotaxis chambers and the chemotactic index of BALF from ADA control and ADA Ϫ/Ϫ mice was determined. Purified eosinophils exhibited little chemotactic activity toward BALF from the lungs of ADA control mice; however, substantial chemotactic activity was seen in ADA Ϫ/Ϫ BALF (Fig. 10). Activation of the A 3 R by treatment with the A 3 R agonist IB-MECA decreased chemotaxis toward BALF from ADA Ϫ/Ϫ mice as well as toward the positive control eotaxin 1. This inhibition of chemotaxis was lost when eosinophils were incubated with the A 3 R antagonist MRS 1523 together with IB-MECA. These findings demonstrate that BALF from ADA Ϫ/Ϫ mice is chemotactic for eosinophils, and that A 3 signaling can block this chemotaxis ex vivo.

Discussion
Adenosine is a signaling molecule that is generated in response to tissue damage and hypoxia. High levels of this nucleoside are found in the airways of asthmatics (3,4), suggesting adenosine signaling may play a role in the exacerbation of this disease. However, the mechanisms by which adenosine influences aspects of lung disease are not fully appreciated. In the current study, we provide novel evidence that A 3 R signaling contributes to airway eosinophilia and mucus production in a model of ADA deficiency where lung adenosine levels are chronically elevated.
Transcript levels for the A 3 R are elevated in the lungs of asthma and COPD patients, where expression is localized to eosinophilic infiltrates (15). Similarly, we found that A 3 R transcripts are elevated in the lungs of ADA Ϫ/Ϫ mice where transcripts localized to sites of eosinophilic inflammation. Increased levels of A 3 R transcripts were also seen in the BALF of allergen-challenged mice where the predominant infiltrate was eosinophils, and analysis of eosinophils purified from peripheral blood revealed that the A 3 R is the most abundant adenosine receptor in eosinophils. It is not clear from these studies whether or not the levels of A 3 R, particularly at the cell surface, change in response to inflammatory cues; however, the expression of the A 3 R in both circulating and pulmonary eosinophils suggest that it may play a role in regulating eosinophil function. The exact role of the eosinophil in asthma is not fully understood; however, its presence in the airways of patients with severe asthma suggests that this cell may contribute to the exacerbation of airway disease by damaging epithelial cells and contributing to airway remodeling (1). Thus, the presence of the A 3 R on human eosinophils (16,25), together with the high levels of adenosine found in the lungs of asthmatics (3,4), suggest that A 3 signaling may play an important role in regulating eosinophil function in the asthmatic lung.
ADA Ϫ/Ϫ mice exhibit adenosine-dependent airway and lung eosinophila in association with elevations in lung adenosine levels (5). Contribution of A 3 signaling to lung inflammation and damage in the lungs of ADA Ϫ/Ϫ mice was conducted using both pharmacologic and genetic approaches. The pharmacologic approach consisted of treatment of ADA Ϫ/Ϫ mice with a selective A 3 R antagonist (MRS 1523), which has been used successfully in vivo in mice (22,34). The genetic approach entailed the generation of ADA/A 3 double knockout mice. Similar results were seen with both methods and suggest that A 3 R signaling contributes to proinflammatory features of adenosine in this model. Closer examination of eosinophils revealed no change in the degree of peripheral blood eosinophilia in ADA Ϫ/Ϫ mice following disruption of A 3 signaling suggesting this signaling pathway is not involved in the production or mobilization of eosinophils from the bone marrow. However, the reduction of BALF eosinophilia following antagonism and removal of the A 3 R suggests A 3 R signaling is involved in the migration of eosinophils from the circulation to the airways.
Diminished airway eosinophilia following the disruption of A 3 signaling is in opposition to studies performed in human eosinophils ex vivo, where chemotaxis of purified eosinophils toward known chemotactic agents was blocked by A 3 R activation (15,18). This discrepancy could be due to differences in mouse and human eosinophils or to differences attributed to the ex vivo nature of the chemotaxis experiments performed. Our examination of A 3 R signaling on mouse eosinophils ex vivo revealed that activation of the A 3 R decreases chemotaxis of murine eosinophils toward ADA Ϫ/Ϫ BALF as well as eotaxin I, suggesting that the impact of A 3 R signaling on migration ex vivo is similar in human and mouse eosinophils. Furthermore, our findings demonstrate that significant differences exist between the impact of A 3 R signaling on eosinophil migration ex vivo and in the whole animal. It is therefore likely that the diminished airway eosinophilia seen in the lungs of ADA Ϫ/Ϫ mice following disruption of A 3 R signaling is not a cell autonomous effect of eosinophils. Rather, disruption of A 3 R signaling in ADA Ϫ/Ϫ mice must impact the expression or activity of key regulatory molecules from other cells that express the A 3 R that in turn impact eosinophil migration. The A 3 R is expressed on murine mast cells (22), airway macrophages (6), and airway epithelial cells (Fig. 2) (6), all of which may produce regulatory molecules that can impact eosinophil migration. As an attempt to address this issue, the levels of key regulatory cytokines and chemokines were measured in the lungs of ADA Ϫ/Ϫ mice with and without disruption of A 3 R signaling. Levels of key eosinophil regulatory cytokines (IL-5, IL-13) and chemokines (eotaxin I, TARC, MCP-3) were elevated in ADA Ϫ/Ϫ lungs, and these levels were not diminished following antagonism or removal of the A 3 R, suggesting regulation of these molecules is not involved in preventing airway eosinophilia in response to disrupted A 3 R signaling. Additional studies are needed to determine the impact of A 3 R signaling on the activities of key regulators of eosinophil migration into and through tissues, including cell adhesion molecules (42), extracellular matrix components (43) and proteases (44), all of which are actively involved in eosinophil trafficking in the lung.
The intracellular mechanisms by which A 3 R signaling influences eosinophil chemotaxis are not known, but may involve the regulation of intracellular Ca 2ϩ levels. The A 3 R is coupled to G␣ i (12), and its activation on eosinophils can elevate intracellular Ca 2ϩ levels (25). Similar responses have been observed following A 3 R engagement on mouse mast cells (22,45), where A 3 R directed increases in intracellular Ca 2ϩ are thought to be mediated by activation of PI3K activity through its interaction with ␤␥ subunits (45,46). Elevating intracellular Ca 2ϩ in eosinophils via A 3 R signaling may promote eosinophil chemotaxis. In addition to influencing chemotaxis, A 3 R engagement on eosinophils may also influence eosinophil survival (47). A 3 R engagement can protect rat mast cells from apoptosis by a pathway that involves activation of PI3K and phosphorylation of protein kinase B (47). In a similar manner, A 3 R engagement on eosinophils may promote their survival at sites of inflammation and in so doing serve a proinflammatory role.
In addition to expression on murine eosinophils, A 3 R expression was evident in mucus-producing cells in the bronchial airways of ADA Ϫ/Ϫ mice. Similar patterns of A 3 R expression have recently been observed in airway mucus-producing epithelium of mice overexpressing IL-13 (6) and in mice challenged with OVA (H. Young, unpublished observations). Therefore, the up-regulation of A 3 R expression in airway epithelial cells appears to be a universal feature of the mucus metaplasia seen in mouse experimental models of asthma. Whether or not the A 3 R is also expressed on mucusproducing cells of the asthmatic lung is not known, nor has the potential function of A 3 R signaling on this cell type been explored. Results in the current study demonstrate that the mucus production in the airways of ADA Ϫ/Ϫ mice can be prevented by antagonism or removal of the A 3 R suggesting that A 3 R signaling is important for mucus metaplasia in this model. However, it is not clear at this stage whether the decrease in mucus production results from direct effects of A 3 R signaling on mucus-producing cells, or is an effect of preventing airway eosinophilia, which has been shown to be associated with mucus production (48,49). Determining the role of the A 3 R on mucus-producing cells will provide important new insight into how adenosine signaling can impact chronic lung disease.
In summary, we have demonstrated that A 3 R levels are elevated in the lungs of ADA Ϫ/Ϫ mice that exhibit adenosine-mediated lung disease. Treatment of ADA Ϫ/Ϫ mice with a selective A 3 R antagonist or genetically removing this receptor prevented airway inflammation and mucus production, suggesting that A 3 R signaling plays an important role in regulating these aspects of chronic lung disease. Disruption of A 3 R signaling in these models appears to function to prevent the migration of eosinophils into the airways suggesting that A 3 R signaling plays a role in regulating the trafficking of this important effector cell in the lung. Thus, in environments where adenosine levels are elevated, such as the lungs of asthmatics (3,4), A 3 R antagonism may provide a mechanism for reducing airway eosinophilia.